The Journal of Allergy and Clinical Immunology
Volume 121, Issue 1 , Pages 257-258 , January 2008

Anti-IgE (omalizumab): A new therapeutic approach for chronic rhinosinusitis

  • Image Result

    MRI scans demonstrate the improvement of mastoiditis, sinus ventilation, and mucosal edema after anti-IgE treatment (B, D) in contrast with pretreatment MRI (A, C). The reduction of mucosa swelling an

    MRI scans demonstrate the improvement of mastoiditis, sinus ventilation, and mucosal edema after anti-IgE treatment (B, D) in contrast with pretreatment MRI (A, C). The reduction of mucosa swelling and the increase of nasal patency enables the patient to undergo a 20-minute closed-mouth scan without any difficulties (D), in contrast with the open-mouth scan necessary for the pretreatment condition (C).

 Disclosure of potential conflict of interest: T. A. Luger has consulting arrangements with Novartis, Abbott, Schering-Plough, Serono, Wyeth, Hermal, Symrise, CERIES, Danone, and Shire; has received grant support from Novartis; and is on the speakers' bureau for Novartis Pierre Fabre, Inneov, and Leo Pharma. R. Brehler has consulting arrangements with Novartis. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(07)01830-1

doi: 10.1016/j.jaci.2007.09.036

The Journal of Allergy and Clinical Immunology
Volume 121, Issue 1 , Pages 257-258 , January 2008

Article Tools

* Image Usage & Resolution